Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection
Daniel R. Goldstein, Bethany M. Tesar, Shizuo Akira, Fadi G. Lakkis
Daniel R. Goldstein, Bethany M. Tesar, Shizuo Akira, Fadi G. Lakkis
View: Text | PDF
Article

Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection

  • Text
  • PDF
Abstract

The Toll-like receptors (TLRs) are recently discovered germline-encoded receptors on APCs that are critically important in innate immune recognition of microbial pathogens. However, their role in solid-organ transplantation is unknown. To explore this role, we employed a skin allograft model using mice with targeted deletion of the universal TLR signal adaptor protein, MyD88. We report that minor antigen–mismatched (HY-mismatched) allograft rejection cannot occur in the absence of MyD88 signaling. Furthermore, we show that the inability to reject these allografts results from a reduced number of mature DCs in draining lymph nodes, leading to impaired generation of anti–graft-reactive T cells and impaired Th1 immunity. Hence, this work demonstrates that TLRs can be activated in a transplant setting and not solely by infections. These results link innate immunity to the initiation of the adaptive alloimmune response.

Authors

Daniel R. Goldstein, Bethany M. Tesar, Shizuo Akira, Fadi G. Lakkis

×

Figure 3

Options: View larger image (or click on image) Download as PowerPoint
Restoration of allograft rejection by provision of either WT donor or re...
Restoration of allograft rejection by provision of either WT donor or recipient APCs. To restore WT recipient or donor APCs, WT females were transplanted with skin from male MyD88–/– donors (squares) or MyD88–/– females were transplanted with WT male skin (diamonds). All recipients in both groups consequently rejected their grafts with significantly inferior survival times versus MyD88–/– recipients of MyD88–/– male grafts (circles) (P = 0.001 in both cases). However, survival times were significantly longer than those of female MyD88+/+ recipients of male MyD88+/+ allografts (triangles) (P = 0.001 vs. MyD88–/– → MyD88+/+; P = 0.003 vs. MyD88+/+ → MyD88–/–).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts